GleamWall
中文EN

LTRN Lantern Pharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1763950 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY27.2%
TTM EPS YoY17.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-250.6%
ROA-124.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets83.5%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$11.51M$16.13M
SG&A expense$6.46M$6.09M
Operating income-$17.98M-$22.22M
Pretax income$16.98M—
Net income-$17.12M-$20.78M
EBITDA-$17.96M-$22.20M
EPS (basic)-1.57-1.93
EPS (diluted)-1.57-1.93
Weighted avg. shares (diluted)10.90M10.76M
Balance sheet
Cash & equivalents$4.42M$7.51M
Short-term investments$5.70M$16.50M
Current assets$10.80M$25.25M
PP&E, net$31,875$47,440
Total assets$11.04M$25.57M
Current liabilities$4.50M$4.33M
Total liabilities$4.50M$4.38M
Shareholders' equity$6.53M$21.19M
Shares outstanding11.25M10.78M
Cash flow statement
Operating cash flow-$15.68M-$17.81M
Capital expenditure$1,715$12,595
Free cash flow-$15.68M-$17.83M
Investing cash flow$11.06M$3.37M
Financing cash flow$1.50M$66,710
Depreciation & amortization$17,280$17,282
Stock-based compensation$651,000$652,000

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.